Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Clark Paramore"'
Autor:
Farrukh Shah, Paul Telfer, Mark Velangi, Shivan Pancham, Robert Wynn, Sally Pollard, Elizabeth Chalmers, Jonathan Kell, Angela M. Carter, Joe Hickey, Clark Paramore, Minesh Jobanputra, Kate Ryan
Publikováno v:
eJHaem, Vol 2, Iss 4, Pp 738-749 (2021)
Abstract Objectives We evaluated routine healthcare management, clinical status and patient‐ and carer‐reported outcomes in UK paediatric and adult patients with transfusion‐dependent β‐thalassaemia (TDT). Methods A multi‐centre, observati
Externí odkaz:
https://doaj.org/article/0e55f29da6df4ad2860859fcc13a2116
Autor:
Anuraag R. Kansal, Odette S. Reifsnider, Sarah B. Brand, Neil Hawkins, Anna Coughlan, Shujun Li, Lael Cragin, Clark Paramore, Andrew C. Dietz, J. Jaime Caro
Publikováno v:
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
Background Standard of care (SoC) for transfusion-dependent β-thalassemia (TDT) requires lifelong, regular blood transfusions as well as chelation to reduce iron accumulation. Objective This study investigates the cost-effectiveness of betibeglogene
Externí odkaz:
https://doaj.org/article/d6cb861054544eae9f3fd0425864a1ec
Publikováno v:
The Patient
Background and Objective Transfusion-dependent β-thalassemia (TDT) is a rare genetic disease characterized by a deficiency of functional β-globin, ultimately leading to lifelong dependence on blood transfusions. There is little patient- and caregiv
Autor:
Katie D. Stewart, Hayley Karn, L Clark Paramore, Louis S. Matza, Minesh Jobanputra, Andrew C Dietz
Publikováno v:
The European Journal of Health Economics
Objectives Transfusion-dependent β-thalassemia (TDT) is a genetic disease that affects production of red blood cells. Conventional treatment involves regular red blood cell transfusions and iron chelation, which has a substantial impact on quality o
Autor:
J. Jaime Caro, Anna Coughlan, Clark Paramore, Odette Reifsnider, Sarah Brand, Andrew C. Dietz, Neil Hawkins, Lael Cragin, Shujun Li, Anuraag R. Kansal
Publikováno v:
Journal of Market Access & Health Policy
article-version (VoR) Version of Record
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
article-version (VoR) Version of Record
Journal of Market Access & Health Policy, Vol 9, Iss 1 (2021)
Background: Standard of care (SoC) for transfusion-dependent β-thalassemia (TDT) requires lifelong, regular blood transfusions as well as chelation to reduce iron accumulation. Objective: This study investigates the cost-effectiveness of betibegloge
Publikováno v:
Clinical therapeutics. 42(2)
Purpose β-Thalassemia is an inherited blood disorder characterized by reduced or no production of adult hemoglobin. Systematic identification of the burden of β-thalassemia with contemporary treatments is lacking in published literature. Thus, a ga
Autor:
Mark Velangi, Elizabeth Chalmers, Paul Telfer, Farrukh Shah, Joe Hickey, Jonathan Kell, Sally Pollard, Minesh Jobanputra, Robert Wynn, Shivan Pancham, Clark Paramore, Kate Ryan
Publikováno v:
Value in Health. 22:S868-S869
Autor:
Lakshmanan Krishnamurti, Julie Kanter, Yuchen Ding, Janet L. Kwiatkowski, John F. Tisdale, Meghan E. Gallagher, Markus Y. Mapara, Mark C. Walters, Sunita Goyal, Ren Chen, Alexis A. Thompson, Clark Paramore
Publikováno v:
Blood. 136:10-10
Background In patients with sickle cell disease (SCD), health-related quality of life (HRQoL) is worse than in the general population and comparable or worse than in patients with other chronic or painful diseases such as cystic fibrosis or cancer. T
Autor:
Anuraag R. Kansal, Rami Ben-Joseph, Jill A. Bell, Clark Paramore, Pamela Holly, Diana I. Brixner, Douglas S. Burgoyne, Abhishek Chitnis
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 22:358-366
Immediate-release (IR) hydrocodone is the most widely prescribed opioid in the United States; however, little is known about the utilization patterns and duration of opioid use among patients prescribed IR hydrocodone. A better understanding of the u
Publikováno v:
Therapeutic innovationregulatory science. 50(5)
In a rapidly changing health care environment, it is more important than ever that pharmaceutical manufacturers improve the quality and efficiency of their research and development efforts in order to help ensure the right drug gets to the right pati